Equities

Mentice AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mentice AB

Actions
  • Price (SEK)13.65
  • Today's Change0.05 / 0.37%
  • Shares traded849.00
  • 1 Year change-42.18%
  • Beta0.5755
Data delayed at least 15 minutes, as of Feb 09 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mentice AB is a Sweden-based medical technology company. It provides software and hardware simulation solutions and related services for endovascular therapies. The Company’s solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Company’s solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The Company also covers neurovascular, cardiovascular and peripheral interventions, among others. It is active globally.

  • Revenue in SEK (TTM)274.49m
  • Net income in SEK-43.31m
  • Incorporated1998
  • Employees121.00
  • Location
    Mentice ABOdinsgatan 10GOETEBORG 411 03SwedenSWE
  • Phone+46 313399400
  • Fax+46 313399499
  • Websitehttps://www.mentice.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Boule Diagnostics AB512.66m-80.68m194.17m186.00--1.15--0.3787-2.09-2.0913.334.341.034.614.042,268,420.00-16.14-9.09-28.43-13.2842.8843.62-15.74-11.160.775323.700.5491---2.252.28-1,287.41--7.84--
Subgen AI AB0.00-64.18m209.86m15.00---------544.10-544.100.00-25.110.00----0.00-188.83---403.12-------------4.46-----100.00--16.86------
SciBase Holding AB (publ)36.58m-90.39m219.52m34.00--3.93--6.00-0.2487-0.24870.09780.06740.66481.293.231,143,250.00-164.26-75.65-244.76-101.0166.0465.08-247.08-256.982.07-11.750.00--27.7926.21-9.97---20.49--
Prolight Diagnostics AB (publ)0.00-35.57m225.48m21.00--1.24-----4.03-4.030.0015.080.00----0.00-19.97---24.07--------------0.00------80.11---1.65--
Integrum AB97.00m-29.85m228.79m37.00--1.21--2.36-1.37-1.374.507.260.52530.8283.402,487,052.00-16.17-3.58-17.87-4.0875.6183.88-30.78-6.471.88--0.025---12.5027.78-864.22--103.14--
Clinical Laserthermia Systems AB21.27m-38.38m238.40m16.00--3.30--11.21-5.02-5.021.082.320.32084.584.841,329,313.00-57.98-116.28-63.60-248.44-63.75-556.78-180.75-872.822.55-5.790.0039--127.0467.4740.32------
Karolinska Development AB1.74m-135.74m243.69m8.00--0.0789--140.21-0.4096-0.40960.00523.280.0015--0.6263217,250.00-11.69-2.23-11.78-2.37-----7,810.36-1,161.99---1.490.0017---8.74-11.49-250.41------
ContextVision AB112.48m3.57m268.61m44.0075.972.9723.592.390.04910.04911.581.250.95751.744.153,020,009.003.0430.513.7145.0797.6298.493.1728.494.70--0.0847---1.156.51-24.6027.25-30.69--
INIFY Laboratories AB20.10m-61.30m288.67m34.00--2.20--14.36-1.15-1.150.37291.730.19282.963.12863,607.90-58.78---58.78--85.20---304.93------0.00--1,000.67--3.15------
Acarix AB6.92m-52.44m314.53m8.00--8.17--45.47-0.0472-0.04720.00620.03430.11960.16672.77864,750.00-90.68-74.33-102.27-86.4786.1582.37-757.98-1,298.777.93-805.720.00---0.624927.2814.97------
Mentice AB274.49m-43.31m382.51m121.00--3.04--1.39-1.68-1.6810.524.480.96631.603.942,095,328.00-15.25-6.64-31.60-11.9190.4084.80-15.78-8.530.845-30.100.116--6.1114.22-553.89--32.86--
Ortoma AB77.19m-7.52m469.31m10.00--2.9889.886.08-0.2027-0.20272.084.450.42433.9539.137,530,537.00-4.13-9.37-4.45-10.4341.26158.24-9.74-78.903.02--0.00--28.77--46.83---0.5751--
Q linea AB8.40m-188.37m485.10m83.00--2.02--57.78-93.10-93.102.1212.690.05710.54094.3789,308.51-128.17-71.92-306.62-84.15-110.15-303.58-2,243.85-3,994.181.28-62.880.3537---46.8018.645.45---49.88--
Bactiguard Holding AB228.77m-7.84m509.12m153.00--1.8212.972.23-0.2238-0.22386.538.990.3813.446.911,495,216.00-1.31-8.02-1.86-10.1363.7848.56-3.43-25.101.38-0.33870.3410---12.644.2273.69---17.92--
Modulight Oyj72.12m-49.18m527.12m71.00--1.09--7.31-0.1172-0.11720.17271.070.1254-0.79434.78102,484.90-8.55-9.90-9.25-10.66129.94119.43-68.15-88.503.46--0.081--1.74-10.6545.65--24.38--
Data as of Feb 09 2026. Currency figures normalised to Mentice AB's reporting currency: Swedish Krona SEK

Institutional shareholders

13.72%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Jun 20242.00m7.10%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Jun 2024804.28k2.86%
Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025607.45k2.16%
Andra AP-fondenas of 30 Jun 2024452.17k1.61%
Quartile Fonder ABas of 28 Nov 20250.000.00%
Lonvia Capital SASUas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.